• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

朝向基于吡唑啉的 MAO 抑制剂的选择性和可逆性发展：合成、生物评估和对接研究。

Towards development of selective and reversible pyrazoline based MAO-inhibitors: Synthesis, biological evaluation and docking studies.

机构信息

Department of Pharmaceutical Sciences, Birla Institute of Technology, Mesra, Ranchi 835 215, India.

出版信息

Bioorg Med Chem Lett. 2010 Jan 1;20(1):132-6. doi: 10.1016/j.bmcl.2009.11.015. Epub 2009 Nov 12.

DOI:10.1016/j.bmcl.2009.11.015
PMID:19945874
Abstract

Ten novel 3,5-diaryl pyrazolines were synthesized and investigated for their monoamine oxidase (MAO) inhibitory property. All the molecules were found to be reversible and selective inhibitor for either one of the isoform (MAO-A or MAO-B). Further insights in the theoretical evaluation of the possible interactions between the compounds and monoamine oxidases (MAO-A or MAO-B) have been developed through docking studies. The theoretical values are in congruence with their experimental values.

摘要

合成了 10 种新型 3,5-二芳基吡唑啉，并研究了它们对单胺氧化酶（MAO）的抑制作用。所有分子均被发现为 MAO-A 或 MAO-B 同工型的可逆和选择性抑制剂。通过对接研究进一步深入了解了化合物与单胺氧化酶（MAO-A 或 MAO-B）之间可能相互作用的理论评估。理论值与实验值相符。

相似文献

1
Towards development of selective and reversible pyrazoline based MAO-inhibitors: Synthesis, biological evaluation and docking studies.朝向基于吡唑啉的 MAO 抑制剂的选择性和可逆性发展：合成、生物评估和对接研究。
Bioorg Med Chem Lett. 2010 Jan 1;20(1):132-6. doi: 10.1016/j.bmcl.2009.11.015. Epub 2009 Nov 12.
2
Development of selective and reversible pyrazoline based MAO-A inhibitors: Synthesis, biological evaluation and docking studies.基于吡唑啉的选择性和可逆单胺氧化酶-A 抑制剂的开发：合成、生物评价和对接研究。
Bioorg Med Chem. 2010 Mar 1;18(5):1875-81. doi: 10.1016/j.bmc.2010.01.043. Epub 2010 Jan 25.
3
Pyrazoline based MAO inhibitors: synthesis, biological evaluation and SAR studies.基于吡唑啉的 MAO 抑制剂：合成、生物评价和 SAR 研究。
Bioorg Med Chem Lett. 2011 Jul 15;21(14):4296-300. doi: 10.1016/j.bmcl.2011.05.057. Epub 2011 May 25.
4
Development of selective and reversible pyrazoline based MAO-B inhibitors: virtual screening, synthesis and biological evaluation.基于吡唑啉的选择性和可逆单胺氧化酶-B 抑制剂的开发：虚拟筛选、合成与生物评价。
Bioorg Med Chem Lett. 2011 Apr 1;21(7):1969-73. doi: 10.1016/j.bmcl.2011.02.030. Epub 2011 Feb 13.
5
Synthesis and molecular modeling of some novel hexahydroindazole derivatives as potent monoamine oxidase inhibitors.一些新型六氢吲唑衍生物作为强效单胺氧化酶抑制剂的合成与分子模拟
Bioorg Med Chem. 2009 Sep 15;17(18):6761-72. doi: 10.1016/j.bmc.2009.07.033. Epub 2009 Jul 23.
6
Pyrazoline-based mycobactin analogues as MAO-inhibitors.基于吡唑啉的分枝菌素类似物作为单胺氧化酶抑制剂
Bioorg Med Chem Lett. 2008 Dec 15;18(24):6362-8. doi: 10.1016/j.bmcl.2008.10.084. Epub 2008 Nov 1.
7
Synthesis, molecular modeling studies and selective inhibitory activity against MAO of N1-propanoyl-3,5-diphenyl-4,5-dihydro-(1H)-pyrazole derivatives.N1-丙酰基-3,5-二苯基-4,5-二氢-(1H)-吡唑衍生物的合成、分子建模研究及其对单胺氧化酶的选择性抑制活性
Eur J Med Chem. 2008 Oct;43(10):2262-7. doi: 10.1016/j.ejmech.2007.12.026. Epub 2008 Jan 6.
8
Synthesis, molecular modeling studies, and selective inhibitory activity against monoamine oxidase of 1-thiocarbamoyl-3,5-diaryl-4,5-dihydro-(1H)- pyrazole derivatives.1-硫代氨基甲酰基-3,5-二芳基-4,5-二氢-(1H)-吡唑衍生物的合成、分子模拟研究及其对单胺氧化酶的选择性抑制活性
J Med Chem. 2005 Nov 17;48(23):7113-22. doi: 10.1021/jm040903t.
9
Synthesis and molecular modelling of novel substituted-4,5-dihydro-(1H)-pyrazole derivatives as potent and highly selective monoamine oxidase-A inhibitors.新型取代-4,5-二氢-(1H)-吡唑衍生物作为强效且高度选择性单胺氧化酶-A抑制剂的合成与分子建模
Chem Biol Drug Des. 2006 Mar;67(3):206-14. doi: 10.1111/j.1747-0285.2006.00367.x.
10
Synthesis and selective inhibitory activity of 1-acetyl-3,5-diphenyl-4,5-dihydro-(1H)-pyrazole derivatives against monoamine oxidase.1-乙酰基-3,5-二苯基-4,5-二氢-（1H）-吡唑衍生物对单胺氧化酶的合成及选择性抑制活性
J Med Chem. 2004 Apr 8;47(8):2071-4. doi: 10.1021/jm031042b.

引用本文的文献

1
Diverse Pharmacological Potential of different Substituted Pyrazole Derivatives.不同取代吡唑衍生物的多样化药理学潜力。
Curr Org Synth. 2024;21(7):858-888. doi: 10.2174/0115701794260444230925095804.
2
Structure-Based Design of Novel MAO-B Inhibitors: A Review.基于结构的新型 MAO-B 抑制剂设计：综述。
Molecules. 2023 Jun 16;28(12):4814. doi: 10.3390/molecules28124814.
3
Oxime Esters: Flexible Building Blocks for Heterocycle Formation.肟酯：杂环形成的灵活结构单元。
Top Curr Chem (Cham). 2023 May 18;381(4):17. doi: 10.1007/s41061-023-00431-y.
4
Pyrazoline Containing Compounds as Therapeutic Targets for Neurodegenerative Disorders.含吡唑啉化合物作为神经退行性疾病的治疗靶点
ACS Omega. 2022 Oct 17;7(43):38207-38245. doi: 10.1021/acsomega.2c05339. eCollection 2022 Nov 1.
5
Design, Synthesis, and Biological Evaluation of Novel MAO-A Inhibitors Targeting Lung Cancer.设计、合成及新型 MAO-A 抑制剂针对肺癌的生物学评估。
Molecules. 2022 Apr 30;27(9):2887. doi: 10.3390/molecules27092887.
6
Formal [4 + 1] cycloaddition of generated 1,2-diaza-1,3-dienes with diazo esters: facile approaches to dihydropyrazoles containing a quaternary center.生成的1,2-二氮杂-1,3-二烯与重氮酯的形式[4 + 1]环加成反应：构建含季碳中心二氢吡唑的简便方法。
RSC Adv. 2019 Jan 11;9(3):1487-1490. doi: 10.1039/c8ra08909d. eCollection 2019 Jan 9.
7
Coumarin-Chalcone Hybrids as Inhibitors of MAO-B: Biological Activity and In Silico Studies.香豆素-查尔酮杂合体作为 MAO-B 的抑制剂：生物活性和计算研究。
Molecules. 2021 Apr 22;26(9):2430. doi: 10.3390/molecules26092430.
8
Curcumin-based pyrazoline analogues as selective inhibitors of human monoamine oxidase A.基于姜黄素的吡唑啉类似物作为人单胺氧化酶A的选择性抑制剂。
Medchemcomm. 2018 Jun 8;9(7):1164-1171. doi: 10.1039/c8md00196k. eCollection 2018 Jul 1.
9
N1-benzenesulfonyl-2-pyrazoline hybrids in neurological disorders: Syntheses, biological screening and computational studies.用于神经系统疾病的N1-苯磺酰基-2-吡唑啉杂化物：合成、生物学筛选及计算研究
EXCLI J. 2018 Jan 19;17:126-148. doi: 10.17179/excli2017-871. eCollection 2018.
10
Microwave-assisted synthesis and bioevaluation of new sulfonamides.新型磺胺类化合物的微波辅助合成及生物活性评价
J Enzyme Inhib Med Chem. 2017 Dec;32(1):369-374. doi: 10.1080/14756366.2016.1254207.